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0.69 (−0.24 to 1.00), median DLQI = 10.0 (0.0–30.0). EQ-VAS
and utilities signiﬁcantly correlated with DLQI (Spearman’s coef-
ﬁcient >−0.500, p < 0.0001 in every case). At follow-up
SCORAD signiﬁcantly decreased and patients reported signiﬁ-
cant higher levels of QoL with every score (Student’s paired t
test, p < 0.0001 in every index). SRM (EQ-VAS = 0.85, utility =
0.70, DLQI = 0.89) and ES (EQ-VAS = 0.90, utility = 0.76, DLQI
= 0.81) were signiﬁcant. CONCLUSION: EQ-5D and DLQI are
good to measure QoL related to AD and to evaluate wellbeing
change over time. A routine use of these instruments should be
considered in evaluating consequences of AD and its treatment
on patients’ wellbeing to optimize therapeutic choices.
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Skin problems such as Atopic Dermatitis (AD) cause sensitive
quality of life (QoL) impairment, with major impact on psy-
chosocial state, social relationships and everyday activities.
OBJECTIVE: To evaluate the socioeconomic impact of AD.
METHODS: It was a naturalistic, multicenter, longitudinal,
ambispective (retro-prospective), prevalence-based Cost-Of-
Illness study enrolling adult and pediatric patients with moder-
ate or severe AD and ﬂare-up. Data was on socio-demographic,
clinical severity (with SCORAD, SCORing-Atopic-Dermatitis
index, possible score = 0–100, higher score = higher severity),
economic (direct and indirect costs), intangible costs in terms of
Health-Related-Quality-of-Life (HRQoL), preferences towards
pharmacological treatment. Following results pertain to adult
patients’ HRQoL, evaluated with the disease-speciﬁc DLQI (Der-
matology-Life-Quality-Index, with scores 0–30, higher score =
lower HRQoL) and the generic EQ-5D. RESULTS: A total of 98
valid adult patients (48% male) from 5 Italian dermatological
centres were enrolled; 39.8% patients were 18–27 y.o., 30.6%
were 28–37 y.o., 29.6% were >38 y.o. At enrollment the median
SCORAD was 53.0 (18.4–90.0), the median DLQI was 10.0
(0.0–30.0), the median EQ-VAS (EQ-Visual-Analogue-Scale) 
was 65.0 (0.0–95.0). Concerning the EQ-5D proﬁle, 12.2% of
patients reported moderate problems with “mobility” and
27.6% with “self-care” (nobody reported severe problems),
53.0% moderate/severe problems with “usual activities”, 95.1%
moderate/severe levels of “pain/discomfort”, 65.9% moderate/
severe levels of “anxiety/depression”. After 2 months from enrol-
ment, the SCORAD decreased signiﬁcantly (Wilcoxon-Signed-
Ranks test, p < 0.0001) and patients reported higher levels of
wellbeing (Wilcoxon-Signed-Ranks test for DLQI or EQ-VAS, 
p < 0.0001). Also the EQ-5D proﬁle signiﬁcally got better for
“usual activities” (McNemar test: p < 0.001), “pain/discomfort”
and “anxiety/depression” (McNemar test: p < 0.0001). CON-
CLUSIONS: This is the ﬁrst study evaluating the QoL conse-
quences of AD in Italy. Adults with AD have impaired levels of
HRQoL, worsening during the relapse period. The adoption of
HRQoL instruments can help physicians and decision-makers 
in the adoption of more effective and efﬁcient health care 
technologies.
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OBJECTIVES: Little attention has been paid to determining
whether different language versions of the same patient-reported
outcome (PRO) measure are equivalent and if their use intro-
duces bias into multinational studies in the form of differential
item functioning (DIF). The study was designed to see whether
it is possible to overcome such DIF in the development of PRO
measures. METHODS: Data collected with a draft PRO—the
12-item Quality of Life Index for Children with Atopic Der-
matitis (QoLICAD)—from France, Germany, Italy, The Nether-
lands and USA were analysed. Rasch analyses were applied to
the data from each country to determine item ﬁt and DIF by
culture. Where some but not all items display DIF, it is possible
to treat them as a different item in each country. This procedure
is referred to as “splitting” items. The analysis was then re-run
on the new item sets. RESULTS: Data were available on 691
(52.4%M; mean age 4.4 years) children in the 5 countries. Rasch
analyses applied to the data indicated that, following the removal
of misﬁtting items, there was considerable DIF by country. A
European and separate US QoLICAD were derived. Four items
were deleted and four were split to create a 20-item European
scale that ﬁtted the Rasch model (Chi2 p < 0.002 after bonfer-
roni correction). Five items were deleted before the US scale ﬁtted
the Rasch model (Chi2 p < 0.004 after bonferonni correction).
The European and US data were linked by six common items
allowing pooling of data from an international study. CON-
CLUSIONS: Language adaptations should be conceptually
equivalent to the original. However, DIF by culture may remain.
If data are to be pooled such DIF needs to be assessed and
accounted for. The method illustrated is a suitable way of achiev-
ing this but requires further testing in a clinical trial setting.
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OBJECTIVE: The preferences of patients and their care-givers
should be considered in the development of treatment strategies.
The aim is to establish care-givers’ preferences and their will-
ingness-to-pay (WTP) on different Atopic Dermatitis (AD) treat-
ment options. METHODS: The CODA study was a naturalistic,
multicentre, longitudinal ambispective (retro-prospective),
prevalence based Cost-of-Illness study. Data on patients with
moderate or severe AD enrolled during ﬂare-up were collected.
A discrete-choice-experiment (DCE) was applied to care-givers
of the enrolled children. enrolled patients. The enrolled subjects
had to choose between two different scenarios in 16 pair-wise
comparisons. The following attributes were considered to be
important after interviewing 20 care-givers and 6 physicians: dis-
tribution mode (local-pharmacy vs. hospital-pharmacy), the
delay of The rapeutic-response (4 hours vs. 24 hours vs. 48
hours), duration of therapeutic-response (1 week vs. 4 weeks vs.
8 weeks), long-term side effects (possible vs. no), local side effects
(possible vs. no). In order to obtain the WTP we added cost of
treatment out-of-pocket (€0 vs. €50 vs. €100/month). RESULTS:
The caregivers (98% parents) of 79 valid children ﬁlled in the
